How might this medication affect my hunger cues and adherence to my meal plan
The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function
People who have severe gastrointestinal conditions like inflammatory bowel disease (IBD) or gastroparesis should not go on GLP-1s, and neither should people with a personal or family history of multiple endocrine neoplasia 2A, multiple endocrine neoplasia 2B, medullary thyroid cancer, or pancreatitis
My Life After Losing 62 lbs Losing weight has improved my self-esteem
Therefore, it is biologically plausible that a person losing significant fat with medication could experience the same redistribution of fat-stored compounds observed with other forms of weight loss
An alternative strategy involves engineered probiotics as living nanofactories that secrete GLP-1 analogues directly in the gut [390, 391]